To include your compound in the COVID-19 Resource Center, submit it here.

Disarm and derisk

Disarm’s journey from Atlas seedling to $30M series A

After replicating the effect of sterile alpha and TIR motif containing 1 gene knockout with small molecule SARM1 inhibitors, axon degeneration company Disarm Therapeutics Inc. passed the milestone needed to unlock series A funding from seed

Read the full 364 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers